Ziad A. Massy

 

Professor of Nephrology & Head of Division of Nephrology | Paris West University, Co-Director of Research Unit INSERM U-1018 CESP Team 5 at the UVSQ

Ziad A. Massy is Professor of Nephrology and Head of the Division of Nephrology at the Paris West University (UVSQ) – Ambroise Paré University Hospital, Paris, and Co-Director of Research Unit INSERM U-1018 CESP Team 5 at the UVSQ, Versailles/Villejuif, France.
Prof. Massy was a Member of ERA-EDTA Council and Chair for the ERA-EDTA Registry and Clinical Governance Affairs (until June 2021). He was an advisory board for the EURECAM Working Group, and CKD-MBD WG Working Group, and a current member and former co-chairman of European Uremic Toxins (EUTox) group. He was a Core-member of the Executive KDIGO board.
He obtained “Fondation du Rein” Award at Sept 2010 and Hungarian Society of Nephrology award at November 2015. He was the Recipient of the Légion d’honneur (Legion of Honour, Knight degree), at 2021 received from French President Emmanuel Macron, (a high French decoration to reward most deserving citizens in different fields of activity) for outstanding contributions to promoting nephrology around the world (particularly in south East Asia and Africa).
His research areas of special interest include uremic toxins, cardiovascular disease, vascular calcification, hyperlipidemia, oxidative stress, and chronic renal failure. He has published several original articles, reviews and chapters of books in his domain of interest (H Index via Publish or Perish v6: 96 or Index H via Web of Sciences: 78, Key words massy z or massy za)] – Total Number of Publications, Medline Sept 2022: 606).

 

Presentation:

Individuals at all stages of chronic kidney disease (CKD) have a higher risk of developing cognitive disorders and dementia. Stroke is also highly prevalent in this population and is associated with a higher risk of neurological deterioration, in-hospital mortality, and poor functional outcomes. Evidence from in vitro studies and in vivo animal experiments suggests that accumulation of uremic toxins may contribute to the pathogenesis of stroke and amplify vascular damage, leading to cognitive disorders and dementia. I will summarize current evidence on the mechanisms by which uremic toxins may favour the occurrence of cerebrovascular diseases and neurological complications in CKD.